SCHEMBL7424745

SCHEMBL7424745

CCCc1c[nH]c2cc(C(=O)OC)ccc12

nearest known ligand 0.80

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.80
GPR84 Q9NQS5 1/20 0.57
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
ATM Q13315 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
CDK2 P24941 1/20 0.53
MTNR1A P48039 2/20 0.50
MTNR1B P49286 2/20 0.50
ASH1L Q9NR48 1/20 0.49
KIF11 P52732 1/20 0.49
PARP1 P09874 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
EIF2AK2 P19525 1/20 0.46
NR4A2 P43354 1/20 0.46
IMPDH2 P12268 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5129036 0.90 NPC1 (0.77) NPC1GPR84MEN1KMT2AATM
SCHEMBL10981632 0.90 NPC1 (0.73) NPC1GPR84MEN1KMT2AATM
SCHEMBL10981015 0.90 NPC1 (0.73) NPC1GPR84MEN1KMT2AATM
SCHEMBL10987953 0.90 NPC1 (0.73) NPC1GPR84MEN1KMT2AATM
SCHEMBL10982062 0.90 NPC1 (0.73) NPC1GPR84MEN1KMT2AATM
SCHEMBL11084044 0.90 NPC1 (0.73) NPC1GPR84MEN1KMT2AATM
SCHEMBL12844152 0.89 GPR84 (0.68) NPC1GPR84MEN1KMT2AATM
SCHEMBL273252 0.88 NPC1 (0.78) NPC1GPR84MEN1KMT2ACDK2
SCHEMBL7423854 0.86 NPC1 (0.76) NPC1GPR84MEN1KMT2AATM
SCHEMBL7415036 0.86 NPC1 (0.76) NPC1GPR84MEN1KMT2ACDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902373-B2 asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide PFIZER INC (US) 2011-03-08 US disclosed
US-20080146569-A1 Nicotinamide Derivatives PFIZER INC. 2008-06-19 US disclosed
EP-0820441-B1 INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS FUJISAWA PHARMACEUTICAL CO (JP) 2002-06-26 EP disclosed
US-6358992-B1 Method of inhibiting neoplastic cells with indole derivatives CELL PATHWAYS, INC. 2002-03-19 US disclosed
US-6069156-A Indole derivatives as cGMP-PDE inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-05-30 US disclosed
CN-1187812-A Indole derivatives as CGMP-PDE inhibitors FUJISAWA PHARMACEUTICAL CO (JP) 1998-07-15 CN disclosed
WO-1996032379-A1 INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146569-A1 Nicotinamide Derivatives NNT, NAMPT, NADK NPC1 255/4885GPR84 748/4885MEN1 2003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.